Expertise in
8
conditions

I-te T. Lee

Taitung, TNQ, TW 
Expertise in
8
conditions
Taitung, TNQ, TW 

Overview

I-te Lee practices practicing medicine in Taitung, Taiwan.

Lee is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Maturity Onset Diabetes of the Young, Metabolic Syndrome, Type 2 Diabetes (T2D), Peripheral Neuropathy, and Percutaneous Coronary Intervention (PCI).

They are actively involved in clinical research, co-authoring 145 peer reviewed articles and participating in 6 clinical trials.

Locations

Taitung, TNQ 40200, Taiwan
Other Locations
TPQ 11221, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Radiation
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Enrollment Status: Completed
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

143 Total Publications

Optimizing a Multimodal Large Language Model for Ultrasound-Based Thyroid Nodule Malignancy Classification: A Comparative Study of Few-Shot Learning, Prompt Engineering, and Fine-Tuning.
Optimizing a Multimodal Large Language Model for Ultrasound-Based Thyroid Nodule Malignancy Classification: A Comparative Study of Few-Shot Learning, Prompt Engineering, and Fine-Tuning.
Journal: Diagnostics (Basel, Switzerland)
Published: May 20, 2026

Frequently Asked Questions about I-te T. Lee

Is I-te T. Lee a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. I-te T. Lee is classified as an Distinguished expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does I-te T. Lee participate in research or clinical trials?

Yes. I-te T. Lee has published 143 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of I-te T. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lee's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile